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ABSTRACT 
Purpose of review: There is growing interest in neuromodulation for primary headache 
conditions.  Invasive modalities such as occipital nerve stimulation, deep brain stimulation and 
sphenopalatine ganglion stimulation are reserved for the most severe and intractable patients.  
Non-invasive options such as vagal nerve stimulation (nVNS), supraorbital nerve stimulation 
(nSONS) and transcranial magnetic nerve stimulation (TMS) have all emerged as potentially 
useful headache treatments.  This review examines the evidence base for non-invasive 
neuromodulation in trigeminal autonomic cephalalgias and migraine. 
Recent findings: Although a number of open-label series of non-invasive neuromodulation 
devices have been published there is very little controlled evidence for their use in any 
headache condition.  Open-label evidence suggests that nVNS may have a role in the 
prophylactic treatment of cluster headache and there is limited evidence to suggest it may be 
useful in the acute treatment of cluster and potentially migraine attacks.  There is limited 
controlled evidence to suggest a role for nSONS in the prophylactic treatment of episodic 
migraine but there is no evidence to support its use in cluster headache. TMS may be 
efficacious in the acute treatment of episodic migraine has no controlled evidence to support 
its use as a preventative in any headache condition. 
Summary: Non-invasive neuromodulation techniques are an attractive treatment option with 
excellent safety profiles but their use is not yet supported by high-quality randomized 
controlled trials.   
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INTRODUCTION  
Primary headache conditions, especially migraine, are a cause of significant disability and 
economic burden worldwide.  Although the treatment options for primary headaches have 
progressed with time, there is still a major issue with the efficacy, availability, adverse event 
and tolerability profiles of current pharmaceutical agents.  It is estimated that under 25% of 
chronic migraine patients continue taking oral preventative agents for more than 12 months 
due to lack of efficacy or tolerability issues (1).  In cluster headache (CH), besides the above 
issues with preventative agents, there are major limitations to acute treatments also.  For 
example, subcutaneous sumatriptan is expensive and can only be used twice daily even in those 
with more frequent attacks and the triptans are also contraindicated in those with heart disease 
or uncontrolled blood pressure.  Oxygen, the only other evidence based acute treatment for CH, 
may be effective in the early stages of attack but is often associated with attack recurrence and 
is not as portable as patients would like.   
Neuromodulation techniques have evolved in order to combat some of these issues.  
Neuromodulation works by using electricity or magnetic impulses to manipulate the 
neurotransmitter systems such as serotonin, glutamine and dopamine important in the pain 
neuromatrix (Figure 1).  Invasive neuromodulation therapies such as occipital nerve 
stimulation (ONS), deep brain stimulation (DBS) and sphenopalatine ganglion stimulation 
(SPGS) are all limited for use in highly refractory patients due to their invasive nature and cost 
(2).  However, the recent development of non-invasive neuromodulation therapies for primary 
headache conditions offer a non-surgical approach which may be more accessible and 
acceptable for patients.  Currently available non-invasive neuromodulation technologies 
include supraorbital transcutaneous stimulation, non-invasive vagal nerve stimulation and 
transcranial magnetic stimulation.  With regards to the trigeminal autonomic cephalalgias 
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(TACs) the evidence is limited to non-invasive vagal nerve stimulation and so this review will 
focus on this technology but the potential use of the devices in other primary headache 
conditions will be discussed (Table 1).  
 
NON-INVASIVE VAGAL NERVE STIMULATION (nVNS) 
The vagus nerve is a mixed motor and sensory nerve involved in autonomic, respiratory 
cardiovascular, gastrointestinal and pain systems.  Efferent fibres of the vagal nerve arise from 
the nucleus ambiguus and dorsal motor nucleus of the vagal nerve.  Afferent fibres terminate 
on the area postrema, the spinal nucleus of the trigeminal nerve and the nucleus of the solitary 
tract.  There is anatomical evidence of the role the vagus nerve may play in regulating 
trigeminal pain.  The nucleus of the solitary tract has been shown to receive nociceptive 
afferents from the dura (3).  Studies in rats have also shown that vagus nerve stimulation 
reduces pain and allodynia in the trigeminal distribution, an observation proposed to be 
secondary to an ascending antinoceceptive effect of the vagus nerve on the second order 
neurons of the spinothalamic and spinoreticular tracts (4).  There is also evidence that vagal 
nerve stimulation reduces glutamate levels and firing rate in the spinal trigeminal nucleus.  
Recent neuroimaging studies have suggested that chronic vagus nerve stimulation inhibits 
activation in the thalamus, limbic system, dorsal pons, locus coerulus and nucleus of the 
solitary tract, all structures previously identified as parts of the pain matrix in headache (5) 
(Figure 1).  
Following reports of improvement of migraine in patients with epilepsy receiving invasive 
vagal nerve stimulation, VNS devices were implanted in a limited number of refractory 
headache patients with positive case reports in migraine and cluster headaches (6, 7).  Recently, 
a portable transcutaneous non-invasive vagal nerve stimulator has been developed 
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(GammaCore®) that stimulates the cervical portion of the vagus nerve.  The device is placed 
on the neck and then a mild electrical current is applied to the skin.  The treatment has been 
trialled for both cluster headache and migraine.   
 
nVNS in cluster headache 
Preventative treatment of cluster headache (Table 1) 
The initial potential of nVNS in the preventative treatment of CH was explored in an audit by 
Nesbitt et al. in 2015 (8).  Of 19 patients included, 11 suffered chronic CH (CCH) and eight 
were episodic (ECH).  Seven patients were reported as refractory to drug treatments (9).  The 
preventative regime consisted of two to three stimulations (doses) in the morning and late 
afternoon with stimulation delivered on the side of the neck ipsilateral to the cluster attacks.  
Fifteen patients reported an improvement after one year, with a mean estimated improvement 
of 48% ±9%.  There were no reports of any serious adverse events although two patients 
experienced side-shifting of attacks.  There were problems with this study including the lack 
of placebo, the lack of objectively measured outcomes and the ability of patients to continue 
and change their preventative medications alongside nVNS.  Regards the last point, one patient 
started methysergide, one increased verapamil dosage and one was treated with high dose 
steroids during the study period.  However, it did suggest a potential role for nVNS for the 
preventative treatment of CH. 
A larger prospective, open-label randomised study of nVNS in CCH (the prevention and acute 
treatment of chronic cluster headache or PREVA trial) was then conducted by Gaul et al. in 
2015 (10).  This multicentre trial of 119 patients with CCH compared adjunctive prophylactic 
nVNS plus standard care (n=48) to standard care alone (control) (n=49) for four weeks 
followed by a four-week extension of standard care and nVNS.  The nVNS preventative regime 
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consisted of three 2-minute stimulations five minutes apart administered twice daily to the right 
side of the neck.  The first dose was administered on waking and the second dose seven to 10-
hours later.  Changes in standard care preventative medicines were not allowed.  The intention 
to treat population on which analysis was performed consisted of 45 nVNS and 48 control 
patients.  Adherence of >80% to nVNS treatment was observed in 64.4% of patients in those 
initially randomised to nVNS from the start and 50% in those receiving nVNS during the 
extension phase only.  In the randomised phase, those receiving nVNS had 3.9 (95% 
confidence interval 0.5,7.2; p=0.002) fewer attacks a week than controls.  In the longer-term, 
those using nVNS throughout the extension period reported an additional reduction of two CH 
attacks a week suggestive of increased benefit with continued use.  In those adding nVNS in 
the extension phase, individuals reported a reduction of 3.3 CH attacks a week compared to 
standard care alone (15.7 vs. 12.4; p<0.001).  During the randomised phase, the ≥50% response 
rate was significantly higher in the nVNS group (40%) compared to the control group (8.3%).  
Data suggested that those continuing to use nVNS continued to respond throughout the 
extension phase.  Although no serious adverse events were related to the use of nVNS, seven 
individuals did discontinue due to side effects (feeling hot, malaise, haematoma after planned 
surgery and depression).  At the study end, 65% recommended the nVNS to others and over 
50% were satisfied with their response to nVNS.  Although this study did not have a placebo 
group, it did consist of CCH patients alone and it was felt such patients are less likely to 
undergo periods of spontaneous remission than those with ECH.  
The cost-effectiveness of nVNS for preventative treatment of CCH was recently analysed using 
the PREVA data (11).  Using a model based on German health insurance costs the yearly cost 
of nVNS and standard care was €7096.69 with quality-adjusted life-years (QALY) of 0.607 
compared to €7511.35 with QUALY of 0.522 for standard care alone.  Abortive medication 
costs were 23% lower in the nVNS group than standard care.  Similar analysis applied to a UK 
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perspective found similar results.  On the basis of this data, nVNS appears to generate greater 
benefit for less economic cost then standard care alone.  Given that the model did not include 
possible savings from changes in preventative medications, medical appointments or indirect 
costs (e.g. ability to work), the benefits of nVNS have likely been underestimated in this study. 
Taken together, this open-label evidence appears to suggest that adjunctive prophylactic nVNS 
is a potentially effective, well-tolerated and cost-effective treatment for the prevention of CH.   
 
Acute treatment of cluster headache attacks (Table 1) 
The audit from Nesbitt et al. reported that patients could terminate attacks within 11 minutes 
± 1 minute of device application in the acute setting (8).  The use of nVNS as an acute treatment 
allowed ten patients to reduce their oxygen usage by an estimated 55%, four to stop triptans 
completely and a further nine to reduce triptan intake by 48%.  In the study by Gaul et al. 
patients were given the option to treat three attacks daily in addition to their preventative doses 
with instructions to take normal rescue medication in the attack was not terminated within 15 
minutes (10).  During the randomised phase 93.8% used the device as an acute treatment at 
least once.  However, no evidence was found of a reduction in attack duration or pain intensity 
with acute use.   
On the basis of available open-label data there is little evidence to support the use of nVNS for 
the acute treatment of CH.   
 
nVNS in other TACs (Table 1) 
There are no published data on the use of nVNS in any of the other TACs.  Our own clinical 
observations, on having used it in a handful of paroxysmal hemicrania (PH), hemicrania 
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continua (HC) and short lasting unilateral neuralgiform headache attacks (SUNHA) are that it 
may be useful in some of these conditions as a preventative treatment (PH, HC and SUNHA) 
or when used as an acute treatment (PH).  However, further studies are needed to explore the 
efficacy and safety of nVNS in these rare headache disorders 
 
nVNS in migraine 
Preventative treatment of migraine (Table 1) 
As in CH, there is no controlled evidence to support the use of nVNS in migraine.  However, 
two open-label series have investigated its potential role.  One small study from Magis et al. 
(available in abstract form only) reported outcomes of 12 patients with migraine treated with 
nVNS (12).  Ten patients discontinued the treatment because of lack of efficacy or adverse 
effects.  A recent double-blinded, sham-controlled pilot study of nVNS in the preventative 
treatment of CM examined 59 participants randomised to nVNS or sham for two months before 
receiving open-label nVNS.  Treatment consisted of two doses delivered three times a day.  At 
the end of the blinded phase there had been a 1.9 day reduction in headache days in the active 
compared to 0.2 day change in the sham group.  After six months, those receiving nVNS from 
outset had a mean change of -2.5 headache days a month suggesting that longer use is needed 
to optimise effect.  A study of the preventative role of nVNS in episodic migraine is ongoing. 
 
Acute treatment of migraine (Table 1) 
Three open-label studies have examined the use of nVNS in acute migraine attacks.  The first 
from Goadsby et al. reported on 27 patients with and without aura who were treated with two 
90-second doses at 15-minute intervals during an attack (13).  For all moderate to severe treated 
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attacks, the pain-free rate at two hours was 22% with 43% reporting significant reductions in 
pain scores.  These results are comparable to naproxen 500mg.  Side effects were mild and 
infrequent.  Another study (available in abstract form only) of 22 patients with 79 treated 
attacks showed ≥50% reduction in pain scores at two hours in 46% of patients (12).  The final 
study included 48 patients with CM or high frequency episodic migraine treating 131 attacks 
over a two-week period (14).  Treatment consisted of two 120-second doses at three-minute 
intervals.  At two hours, 64.6% reported ≥50% reduction in pain scores and 39.6% were pain 
free.    Treatment was well tolerated with no major side effects.  nVNS may be effective as an 
acute treatment for migraine but larger controlled studies are needed. 
 
SUPRAORBITAL NERVE STIMULATION 
The supraorbital nerve is derived from the first branch of the trigeminal nerve (V1).  The 
trigeminal nerve is responsible for the relay of nociceptive information from intracranial 
structures such as the dura and large blood vessels.  C-fibres innervating these structures pass 
through the trigeminal ganglion and into the trigeminal nucleus caudalis (TNC) in the pons.  
The TNC extends caudally and connects with the C1-C3 levels of the spinal cord and rostrally 
projects to the thalamus, the superior salivatory nucleus and hypothalamus (Figure 1).  This 
pathway is crucial in the pathophysiology of headache pain and is explored in numerous articles 
(15).  Recent preliminary results from an FDG-PET study in episodic migraine following 
treatment with non-invasive supraorbital nerve stimulation (nSONS) showed a normalisation 
of orbitofrontal hypometabolism, suggesting the treatment has its effect via a neuromodulatory 
effect involving the limbic system and areas of the pain matrix. 
Case reports of supraorbital nerve stimulator percutaneous implants, often alongside occipital 
nerve stimulation, have suggested a possible beneficial effect in migraine, cluster headache and 
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short lasting-unilateral neuralgiform headache attacks with conjunctival injection and tearing 
(16).  However, invasive nerve stimulation is reserved for refractory patients only.  A 
transcutanoues supraorbital nerve stimulator, the Cefaly® device has now been developed to 
provide nSONS and has been granted American Food and Drug Administration (FDA) 
approval in episodic migraine. 
 
nSONS in the trigeminal autonomic cephalalgias  
Currently there is no evidence that nSONS using the Cefaly® device has any role in either the 
acute or preventative treatment of TACs (Table 1).  Our own clinical observations are that the 
device is not useful in either the preventative or acute treatment of TACs.  However, given the 
data on invasive SONS in CCH well planned controlled trials are needed. 
 
nSONS in migraine 
Preventative treatment of episodic migraine (Table 1) 
Pilot trials in 10 patients suggested efficacy and safety of nSONS in episodic migraine (17).  
This led to a randomised sham-controlled multicentre study conducted between 2009-2011.  
The PREvention of Migraine using Cefaly (PREMICE) study included 67 patients with at least 
two migraine attacks a month who were randomised to either verum or sham nSONS for a 
three-month treatment period (18).  Treatment consisted of one 20-minute session daily for 
both groups.  After three-months, migraine days decreased significantly in the active group 
(2.06 days; p=0.023) but not in the sham group (0.32; p=0.608), however, the difference 
between migraine day reduction between groups did not reach statistical significance.  The 
50% responder rate was 38.1% in the active and 12.1% in the sham group (p=0.023).  
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Additional statistical analysis conducted after this publication was performed which discovered 
that those with more frequent migraine derived more benefit from the nSONS (19).  No adverse 
events were recorded in either group.   
A post marketing study of 2313 subjects using nSONS as a preventative agent reported 53% 
(n=1236) to be “satisfied” with treatment in that they continued to use the device post the 40-
day free trial period (20).  However, of those returning the device, 48 subjects had failed to 
even turn the device on and 157 had not used the device for more than 60 minutes.  In total, 
40% of those returning the device (n=431) had failed to comply with treatment and it has been 
calculated that the true non-responder rate could be as low as 18.6%.  No serious adverse events 
were reported. 
 
Acute treatment of episodic migraine (Table 1) 
There is no evidence to support the use of nSONS in the acute treatment of migraine.  The 
original pilot study mentioned above also treated 30 attacks with nSONS with total relief in 
just 13% and partial relief with additional medication in 45%. 
 
TRANSCRANIAL MAGNETIC STIMULATION 
The brain of migraine sufferers is thought to be hyperexcitable, a theory supported by 
transcranial magnetic stimulation studies (21).  This leads to a lowered threshold for cortical 
spreading depression, a process linked to the generation of migraine aura and pain.  
Transcranial magnetic stimulation (TMS) applies a brief single magnetic pulse to the scalp and 
underlying cortex.  This pulse induces electric field potentials in the cortex, alternating 
neurotransmitter levels and disrupting cortical spreading depression (Figure 1).  Animal studies 
Pg. 12 
 
have shown the TMS inhibits cortical spreading depression.  It was extrapolated that in acute 
migraine attacks, TMS could terminate aura and reduce pain levels.  A portable TMS device 
(SpringTMS) was thus developed as a migraine treatment. 
 
TMS in trigeminal autonomic cephalalgias 
There is no evidence to support the use of TMS in TACSs and given that the pathophysiology 
of TACs does not include cortical spreading depression it is unlikely to be a focus of 
investigation in the near future. 
 
TMS in migraine 
Preventative treatment of episodic migraine (Table 1) 
There is no controlled evidence to support the use of TMS in the preventative treatment of 
migraine. 
 
Acute treatment of episodic migraine with and without aura (Table 1) 
A single sham-controlled study on the use of TMS in the acute treatment of migraine with aura 
reported a pain-free at 2h response rate of 39% compared to 22% in sham treated patients, a 
difference that was maintained at 24h (22).  Open-label post-marketing surveys conducted on 
462 subjects using TMS as an acute treatment for migraine with and without aura reported full 
3-month follow-up data on only 190 patients with a discontinuation rate of 55% (23).  The 
group have not provided complete data on their responder rates but stated that 62% reported 
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“some reduction” in migraine pain.  On this evidence, TMS may have a role in the acute 
treatment of migraine but more data is obviously needed.   
 
CONCLUSION 
There is a major unmet need in the currently available treatment options for patients with 
primary headache conditions, including those with trigeminal autonomic cephalalgias.  Non-
invasive neuro-modulation techniques offer potential efficacy combined with highly 
favourable adverse effect profiles.  There is also some suggestion that their cost-effectiveness 
will also prove favourable compared to standard treatments.  However, despite some promising 
initial open-label data, caution has to be used in deciding when to use these treatments.  At 
present, there are no high quality double-blinded randomised controlled trials on the use of any 
non-invasive neuromodulation techniques for primary headache conditions and these will be 
needed before decisions can be made on the true role of non-invasive neuromodulation.  At 
present, these devices should be reserved for those with medication tolerance issues or those 
proving intractable to standard treatments.  Clinicians have a responsibility to explain the 
limited evidence base and possible limitations of these treatment modalities to patients.  
However, if robust evidence on non-invasive neuromodulation techniques can be obtained, 
these treatments are likely to become a valuable part of our management options. 
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